This monthly feature will help readers keep current on new drugs, new indications, dosage forms, and safety-related changes in labeling or use. Efforts have been made to ensure the accuracy of this information; however, if there are any questions, please let me know at danial.baker@wsu.edu.
Comparative agents:
Individual ingredients
Indication:
In combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection
Mechanism of action:
HIV-1 protease inhibitor and CYP3A inhibitor 
Comparative agents: Individual ingredients
Indication:
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both empagliflozin and linagliptin is appropriate
Mechanism of action:
Sodium-glucose co-transporter 2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor 
Comparative agents: None

Indication:
Treat patients with progressive, differentiated thyroid cancer whose disease progressed despite receiving radioactive iodine therapy (radioactive iodine refractory disease)
Mechanism of action:
Kinase inhibitor; receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4) Unanimously to recommend approval of once-daily intravenous and oral treatment of invasive aspergillosis; 8 to 2 with one abstention for approval for the treatment of invasive mucormycosis
Recommended for NON-approval by an FDA advisory panel
Desmopressin Nocduma (Ferring)
Reduce urine voiding in adults who awaken 2 or more times a night to urinate; 10 against, 5 for, and 2 abstentions because of the small size in the clinical trials and the unanswered questions regarding the drug's efficacy and safety.
